About
Portfolio
News
Connect

Select Page

TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based

Oct 8, 2020

TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy Company

Search for:

Recent Posts

Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
Treadwell Announces Two Presentations at the 2020 ASH Annual Meeting Featuring Clinical Trial Updates on Lead Product Candidate, CFI-400945
Treadwell Announces Initiation New Clinical Trial CFI 400945
TIO-Bioventures-Launches-TCRyption-TCR-T-cell-based
Treadwell-Announces-Initiation-Patient-Dosing-TWT-101-Phase

Recent Comments

©2020 TIO Bioventures
Terms of Use / Legal Disclaimer
Design by D&CO

New York Office
41 Madison Avenue, 25th Floor
New York, New York, USA, 10010

Archives

April 2021
December 2020
October 2020
September 2020
August 2020
June 2020

Categories

Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

Whos theme My Theme | Powered by MyPress | Designed by Your Design Agency